ACADIA Pharmaceuticals (ACAD) Competitors

Genmab A/S (NASDAQ:GMAB) and ACADIA Pharmaceuticals (NASDAQ:ACAD) are both medical companies, but which is the better business? We will compare the two businesses based on the strength of their media sentiment, earnings, dividends, valuation, institutional ownership, profitability, risk and analyst recommendations.

Do institutionals & insiders hold more shares of GMAB or ACAD?

7.1% of Genmab A/S shares are owned by institutional investors. Comparatively, 96.7% of ACADIA Pharmaceuticals shares are owned by institutional investors. 1.5% of Genmab A/S shares are owned by insiders. Comparatively, 26.5% of ACADIA Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Does the media favor GMAB or ACAD?

In the previous week, ACADIA Pharmaceuticals had 6 more articles in the media than Genmab A/S. MarketBeat recorded 18 mentions for ACADIA Pharmaceuticals and 12 mentions for Genmab A/S. Genmab A/S's average media sentiment score of 0.72 beat ACADIA Pharmaceuticals' score of 0.52 indicating that Genmab A/S is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Genmab A/S	4 Very Positive mention(s)	0 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
ACADIA Pharmaceuticals	2 Very Positive mention(s)	0 Positive mention(s)	10 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Which has preferable earnings and valuation, GMAB or ACAD?

Genmab A/S has higher revenue and earnings than ACADIA Pharmaceuticals. Genmab A/S is trading at a lower price-to-earnings ratio than ACADIA Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Genmab A/S	$3.12B	4.66	$1.14B	$1.76	12.89
ACADIA Pharmaceuticals	$957.80M	4.26	$226.45M	$1.37	17.81

Do analysts recommend GMAB or ACAD?

Genmab A/S presently has a consensus target price of $37.80, suggesting a potential upside of 66.59%. ACADIA Pharmaceuticals has a consensus target price of $28.00, suggesting a potential upside of 14.75%. Given Genmab A/S's stronger consensus rating and higher probable upside, equities research analysts clearly believe Genmab A/S is more favorable than ACADIA Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Genmab A/S	1 Sell rating(s)	3 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.64
ACADIA Pharmaceuticals	1 Sell rating(s)	6 Hold rating(s)	10 Buy rating(s)	1 Strong Buy rating(s)	2.61

Is GMAB or ACAD more profitable?

Genmab A/S has a net margin of 35.11% compared to ACADIA Pharmaceuticals' net margin of 21.80%. Genmab A/S's return on equity of 18.08% beat ACADIA Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Genmab A/S	35.11%	18.08%	14.52%
ACADIA Pharmaceuticals	21.80%	15.38%	9.68%

Which has more volatility & risk, GMAB or ACAD?

Genmab A/S has a beta of 0.95, suggesting that its share price is 5% less volatile than the S&P 500. Comparatively, ACADIA Pharmaceuticals has a beta of 0.7, suggesting that its share price is 30% less volatile than the S&P 500.

Summary

Genmab A/S beats ACADIA Pharmaceuticals on 11 of the 16 factors compared between the two stocks.